Alle Storys
Folgen
Keine Story von Zur Rose AG mehr verpassen.

Zur Rose AG

EQS-News: Zur Rose-Group acquires mail-order pharmacy Vitalsana


EQS Group-News: Zur Rose Group AG / Key word(s): Mergers & Acquisitions
Zur Rose-Group acquires mail-order pharmacy Vitalsana

23.11.2017 / 07:00

--------------------------------------------------------------------------------
Press release

Zur Rose-Group acquires mail-order pharmacy Vitalsana

Zur Rose Group AG is taking over the mail-order pharmacy Vitalsana B.V. in
Heerlen, as well as the associated service provider ApDG GmbH in Ulm, from
Ströer SE & Co. KGaA. As Europe's leading mail-order pharmacy, the Group is thus
underpinning its strategy oriented towards long-term growth. In the context of
this acquisition, it is pooling a significant proportion of its mail-order
business in the Aachen/Heerlen euro-region and achieving synergy effects along
the entire value chain. With its mail-order pharmacy primarily geared towards
non-prescription drugs, Vitalsana generated revenue of around EUR 30 million in
2016. The transaction is subject to approval by the responsible competition
authorities. It has been agreed not to disclose any financial aspects.

The Zur Rose subsidiary DocMorris in Heerlen and the media company Ströer will
also enter into a strategic partnership, which will contribute further to the
growth of DocMorris. The mail-order pharmacy will continue the successful
marketing model of Vitalsana, still relying on the wide-ranging media offerings,
performance marketing options and data-focused products of Ströer. As a leading
digital multi-channel media company in Europe, Ströer sets pioneering standards
in terms of innovation, quality and targeted marketing.

Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail:  ir@zurrose.com, telephone: +41 52 724 00 64

Media contact
Lisa Lüthi, Head of Corporate Communications
e-mail:  lisa.luethi@zurrose.com, telephone: +41 52 724 08 14

Zur Rose Group
Operating under the "Zur Rose" and "DocMorris" brands, the Swiss-based Zur Rose
Group is Europe's largest online pharmacy and one of Switzerland's leading
wholesale suppliers to medical doctors. Through its business model, it helps to
ensure safe, reliable and high-quality pharmaceutical care, while also excelling
in developing innovative medicines management services to increase the
effectiveness of the medication process. This creation of added value, the
strong focus on patients and the commitment to supply medication at low cost for
the benefit of payors and patients make the Group an important strategic partner
for all healthcare stakeholders.

Zur Rose Group is headquartered in Frauenfeld, from where it also serves the
Swiss market. In Germany and Austria, the Group operates through subsidiaries in
Heerlen (Netherlands) and Halle an der Saale (Germany). Furthermore, it holds a
majority interest in BlueCare in Winterthur, the leading provider of networking
systems in the Swiss healthcare market. Employing more than 800 people at its
various locations, Zur Rose Group generated revenue of CHF 880 million in 2016.

Zur Rose Group AG's shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN
CH0042615283) are traded on SIX Swiss Exchange in accordance with the
International Reporting Standard of SIX Swiss Exchange. The corporate bond
issued in November 2012 for the purpose of financing the DocMorris acquisition
is listed on the SIX Swiss Exchange (Swiss security no. 19972936, ISIN
CH0199729366, ticker symbol ZRO12). zurrosegroup.com

--------------------------------------------------------------------------------
End of Corporate News
--------------------------------------------------------------------------------

Language: English

Company:  Zur Rose Group AG

          Walzmühlestrasse 60

          8500 Frauenfeld

          Switzerland

Phone:    +41 52 724 08 14

Internet: www.zurrosegroup.com

ISIN:     CH0199729366, CH0042615283

Listed:   SIX Swiss Exchange



 

End of News EQS Group News Service

--------------------------------------------------------------------------------

631831  23.11.2017 

Weitere Storys: Zur Rose AG
Weitere Storys: Zur Rose AG